Read on Twitter
My thoughts on $SGMO End Game.
A. They’re either going it alone, partnering almost every asset they have as a way to raise the cash to fund in-vivo Gene Editing research, making them more of an “asset earn-out” company OR
B. Near term data triggers BP to buy them outright.
A. They’re either going it alone, partnering almost every asset they have as a way to raise the cash to fund in-vivo Gene Editing research, making them more of an “asset earn-out” company OR
B. Near term data triggers BP to buy them outright.
$SGMO (2)
If it’s B. Big Pharma Takeout then it’s either an existing partner or a new BP acquirer. So it’s one of six scenarios, in order of likelihood.
1. $PFE
2. $GILD
3. $BIIB
4. $TAK
5. $SNY
6. New acquirer
If it’s B. Big Pharma Takeout then it’s either an existing partner or a new BP acquirer. So it’s one of six scenarios, in order of likelihood.
1. $PFE
2. $GILD
3. $BIIB
4. $TAK
5. $SNY
6. New acquirer
$SGMO (3)
1. Pfizer $PFE : scenario
SB-525 new data is strong, clearly surpassing $BMRN #valrox and setting up 525 as the best-in-class HemA tx. PFE sees the GT platform as a winner & jumps the mkt on the bigger read-thru tx still in the pipeline: #Fabry, buys SGMO outright.
1. Pfizer $PFE : scenario
SB-525 new data is strong, clearly surpassing $BMRN #valrox and setting up 525 as the best-in-class HemA tx. PFE sees the GT platform as a winner & jumps the mkt on the bigger read-thru tx still in the pipeline: #Fabry, buys SGMO outright.
$SGMO (4)
2. Gilead $GILD : scenario
GILD was first to make real overtures to SGMO, even took an equity stake in lieu of deal. They need M&A, and they aren’t going to lose. Emerging TReg‘s = easy bolt on to existing p’ship & even bolsters it. SGMO’s side of HemA + Alz = gravy.
2. Gilead $GILD : scenario
GILD was first to make real overtures to SGMO, even took an equity stake in lieu of deal. They need M&A, and they aren’t going to lose. Emerging TReg‘s = easy bolt on to existing p’ship & even bolsters it. SGMO’s side of HemA + Alz = gravy.
$SGMO (5)
3. Biogen $BIIB : scenario
They just bought 17% of SGMO (!) in massive Alz/Park preclinic asset deal, laying groundwork for a deal, BIIB can block/beat any offer. They need M&A & get SGMO’s side of CART/Oncology, HemA, & all Fabry.
Deal almost pays for itself.
3. Biogen $BIIB : scenario
They just bought 17% of SGMO (!) in massive Alz/Park preclinic asset deal, laying groundwork for a deal, BIIB can block/beat any offer. They need M&A & get SGMO’s side of CART/Oncology, HemA, & all Fabry.
Deal almost pays for itself.
$SGMO (6)
4. Takeda $TAK : scenario
TAK is the stalking horse. They tend to surprise everyone and aggressively jump on M&A. They are one of SGMO’s oldest partners. Huntington’s is a battleground, and TAK may view it alone as a reason to buy them up getting the rest for free.
4. Takeda $TAK : scenario
TAK is the stalking horse. They tend to surprise everyone and aggressively jump on M&A. They are one of SGMO’s oldest partners. Huntington’s is a battleground, and TAK may view it alone as a reason to buy them up getting the rest for free.
$SGMO (7)
5. Sanofi $SNY : scenario
Sickle/Beta-Thal are huge indications. SGMO likely owns BCL1A #Crispr patent in use by $CRSP. Of the Ph1/2 SGMO assets, SNY has 2 of 5. Fabry and MPS are unpartnered. SNY deal would give them 100% of 4 of 5. Add all Fabry + SGMO side of HemA?
5. Sanofi $SNY : scenario
Sickle/Beta-Thal are huge indications. SGMO likely owns BCL1A #Crispr patent in use by $CRSP. Of the Ph1/2 SGMO assets, SNY has 2 of 5. Fabry and MPS are unpartnered. SNY deal would give them 100% of 4 of 5. Add all Fabry + SGMO side of HemA?
$SGMO (8)
6. New Acquirer : scenario
All the other BP partners have paid you to derisk the technology. Owning SGMO’s side of all those deals is worth Billions in milestones at little add’l cost, plus BIC HemA read into Fabry + Cash... and what is the actual “cost” of the deal?
6. New Acquirer : scenario
All the other BP partners have paid you to derisk the technology. Owning SGMO’s side of all those deals is worth Billions in milestones at little add’l cost, plus BIC HemA read into Fabry + Cash... and what is the actual “cost” of the deal?
$SGMO (9)
Final Thoughts:
The more data that comes out, and the more SGMO goes into play for M&A. Post Covid buyback restrictions will Drive M&A and biotech will go quick. $QURE looks poised to get taken out and set a new higher bar for Gene Therapy valuations.
Final Thoughts:
The more data that comes out, and the more SGMO goes into play for M&A. Post Covid buyback restrictions will Drive M&A and biotech will go quick. $QURE looks poised to get taken out and set a new higher bar for Gene Therapy valuations.
